Rationale The mesostriatal dopamine system plays a key role in mediating the reinforcing effects of psychostimulant drugs like cocaine. The muscarinic M 4 acetylcholine receptor subtype is centrally involved in the regulation of dopamine release in striatal areas. Consequently, striatal M 4 receptors could be a novel target for modulating psychostimulant effects of cocaine. Objectives For the first time, we here addressed this issue by investigating the effects of a novel selective positive allosteric modulator of M 4 receptors, VU0152100, on cocaine-induced behavioral and neurochemical effects in mice. Methods To investigate the effect of VU0152100 on the acute reinforcing effects of cocaine, we use an acute cocaine selfadministration model. We used in vivo microdialysis to investigate whether the effects of VU0152100 in the behavioral studies were mediated via effects on dopaminergic neurotransmission. In addition, the effect of VU0152100 on cocaineinduced hyperactivity and rotarod performance was evaluated. Results We found that VU0152100 caused a prominent reduction in cocaine self-administration, cocaine-induced hyperlocomotion, and cocaine-induced striatal dopamine increase, without affecting motor performance. Consistent with these effects of VU0152100 being mediated via M 4 receptors, its inhibitory effects on cocaine-induced increases in striatal dopamine were abolished in M 4 receptor knockout mice. Furthermore, selective deletion of the M 4 receptor gene in dopamine D 1 receptor-expressing neurons resulted in a partial reduction of the VU0152100 effect, indicating that VU0152100 partly regulates dopaminergic neurotransmission via M 4 receptors co-localized with D 1 receptors. Conclusions These results show that positive allosteric modulators of the M 4 receptor deserve attention as agents in the future treatment of cocaine abuse.
Introduction
Midbrain dopaminergic neurons projecting to the striatum are centrally involved in mediating the reinforcing effects of Ditte Dencker and Pia Weikop contributed equally to this work. psychostimulant drugs like cocaine (Wise 1996; Koob et al. 1998) . Acetylcholine (ACh) plays important roles in the regulation of many fundamental functions of the central nervous system, including abuse-related effects of cocaine (Williams and Adinoff 2008; Sofuoglu and Mooney 2009) . ACh exerts its actions through binding to two distinct classes of receptors, i.e., nicotinic and muscarinic receptors in the brain. The muscarinic receptor family consists of five subtypes (M 1 -M 5 ), which control many important central and peripheral functions (Wess 2004; Wess et al. 2007 ). Muscarinic M 4 receptors are highly expressed in striatal areas (Levey 1993; Yasuda et al. 1993) where the cholinergic and dopaminergic neurotransmitter systems converge (Di Chiara et al. 1994 ). In the striatum, M 4 receptors are the predominant muscarinic autoreceptors on cholinergic interneurons (Zhang et al. 2002) but are also expressed on GABAergic projection neurons where they are primarily colocalized with dopamine D 1 receptors and to a lesser extent with D 2 receptors (Weiner et al. 1990; Bernard et al. 1992; Ince et al. 1997) . Striatal D 1 receptors and M 4 receptors exert opposing effects on intracellular cAMP formation (Onali and Olianas 2002) . Mice lacking the M 4 receptor (M4-KO mice) display a "dopamine hypersensitivity" behavioral phenotype (Gomeza et al. 1999; Felder et al. 2001; Tzavara et al. 2004 ), and we recently showed that M 4 receptor deletion increases chronic cocaine self-administration, cocaine-induced dopamine increase in the nucleus accumbens, and cocaine-induced hyperlocomotor activity in mice . Taken together, these data suggest that compounds with agonistic effects on striatal M 4 receptor could inhibit cocaine-induced behavioral effects and striatal dopamine increases.
Centrally active positive allosteric modulators (PAM) of the M 4 receptor have recently been developed, including LY2033298, VU0152099, and VU0152100 (Brady et al. 2008; Chan et al. 2008) . Consistent with findings in M4-KO mice, LY2033298 attenuated apomorphine-induced deficits in pre-pulse inhibition of the startle response and conditioned avoidance response in rats (Chan et al. 2008; Leach et al. 2010) , and VU0152099/VU0152100 potently inhibited amphetamine-induced hyperlocomotion in rats (Brady et al. 2008) . Until now, the effects of M 4 receptor PAMs on the reinforcing properties of drugs of abuse have not been investigated. Here, we addressed this issue by studying the effects of the M 4 receptor PAM, VU0152100, on behavioral and neurochemical effects of cocaine in mice.
Materials and methods
Animals Male NMRI mice (Taconic, Denmark) and M4-KO ) and D1-M4-KO (Jeon et al. 2010) mice on a C57BL/6 background weighing 28-31 g were used in all experiments, except for the acute selfadministration experiment where mice weighing 20-22 g were used. All mice were housed in Makrolon cages (20× 35×15 cm) enriched with cardboard housing and nesting material. The animals were kept at room temperature (22± 2°C) in a 12-h light/dark cycle (lights on at 6:00 a.m.) with free access to food and water. All experiments were performed in the middle of the light cycle between 9:00 a.m. and 4:00 p.m. The mice were allowed to acclimatize to the animal facility for at least 7 days prior to initiation of the experiments. Experiments in transgenic mice were performed on experimentally naïve 10-16-week-old mice. All procedures were conducted in accordance with the guidelines from the Animal Experimentation Inspectorate, Denmark and the European Communities Council Directive of 24 November 1986 (86/609/EEC).
Drugs used for behavioral studies VU0152100 (3-amino-N-84-methoxybenzyl)-4,6-dimethylthieno[2,3-b]pyridine carboxamide was obtained from Axon Medchem (Groningen, The Netherlands). Cocaine hydrochloride was obtained from the Copenhagen University Hospital Pharmacy, Denmark. VU0152100 (0.1-10 mg/kg) was dissolved in 10 % tween 80 and 0.9 % saline solution with pH adjusted to 6-7 using sodium hydroxide (1 M). Cocaine was dissolved in saline. An initial dose-finding study revealed that an intraperitoneal (i.p.) injection of VU0152100 10 mg/kg was sufficient to reduce cocaine (30 mg/kg)-induced hyperlocomotion in mice (data not shown). In all experiments, VU0152100 was administered (i.p.) 40 min prior to cocaine, which was administered subcutaneously (s.c.) or intravenously (i.v.). We have not evaluated the pharmacokinetic properties of VU0152100 in mice but have used the data from a study in rats (Brady et al. 2008) . Haloperidol (Serenase; 5 mg/ml, Janssen-Cilag) was diluted in saline. All drugs were injected in a volume of 10 ml/kg. Chemicals and reagents Dopamine hydrochloride was obtained from Sigma (St. Louis, MO, USA). Metacam was obtained from Boehringer Ingelheim (Copenhagen, Denmark) and sevoflurane from Baxter (Alleroed, Denmark). All other chemicals were purchased from Merck (Darmstadt, Germany) and Fluka Chemie (Buchs, Switzerland). Deionized water was obtained from a MilliQ water purification system (Billerica, Ma, USA).
Acute cocaine self-administration The procedure has been described in detail previously (Sørensen et al. 2008) . The self-administration apparatus consisted of transparent plastic boxes (8×8×8 cm) with a centered frontal nose-poke hole (12 mm diameter) 1 cm above the floor and a centered posterior vertical opening (width 5 mm) through which the tail extended. Dual photocells projected an infrared beam 1 mm in front of the nose-poke hole. Eight NMRI mice were tested at the same time, with interposed shields, preventing the mice from seeing each other during the experiment. Immediately before being placed in the test boxes, the mice were left for approximately 3 min below a 150-W infrared light bulb to induce vasodilatation, thus facilitating the insertion of the needle into their tail veins. The tail was fixed onto a stripe of double-sided adhesive tape. The tape also fixed the tail at its base as well as the needle at the insertion point. A nose-poke interrupted the infrared beam, thus activating the photocell connected to an interface (SG 502, Med Associates Inc.) and thereafter a syringe pump (PHM-100A, Med Associates Inc.) holding a 2-ml syringe connected by 75 cm PVC tubing (0.9 mm inner diameter) to a 27-G infusion needle. A back-check valve between needle and tubing prevented reflux of blood. A fixed ratio 1 schedule was used, with no time-out between nose-poke and infusion, so that each nose-poke induced the i.v. infusion of 1.4 μl cocaine or saline solution. A computer and selfadministration software (Ellegaard Systems, Denmark) were used to control infusions and to record nose-poking behavior. After placing the mouse in the self-administration box for a 10-min habituation period during which nose-poking did not induce infusions, one priming infusion was given by the experimenter immediately before starting a 30-min session. Immediately after the session, the correct placement of the infusion needle was verified by manual infusion of the tested drug by an experimenter blind to the pretreatment as well as to the number of nose-pokes produced, and the animals were quickly sacrificed. Animals were excluded from further analysis if they had not produced at least five nose-pokes during the self-administration session or correct placement of the infusion needle could not be verified.
The mice received an i.p. injection of VU0152100 at doses of 0.1 (n013) or 1.0 (n011) mg/kg or corresponding vehicle (n014), and at 30 min later, they were subjected to the self-administration procedure described above with access to i.v. administration of cocaine at 0.03 mg/kg/infusion, previously shown to be the peak dose for inducing selfadministration in NMRI mice (22) . A control group (n011) received vehicle i.p. followed by saline i.v.
Locomotor activity measurements The locomotor activity cages (Ellegaard Systems, Denmark) were equipped with 5×8 infrared light sources plus photocells. The light beams crossed the cage 1.8 cm above the bottom of the cage. During the test session, locomotor activity was recorded as crossings of infrared light beams. The recording of a motility count required interruption of two adjacent light beams, thus avoiding counts induced by stationary movements of the mice. All experiments were conducted in a clean cage with a scant lining of bedding material. Initially, NMRI mice were placed in the test cages for a 30-min habituation period followed by i.p. administration of VU0152100 (0.1-10 mg/ kg) or vehicle. Forty minutes later, all mice were injected with 30 mg/kg of cocaine (s.c.), and locomotor activity was measured for an additional 3 h.
Rotorod test
The effects of VU0152100 on motor performance were evaluated using an accelerating rotorod model (Ugo Basile 7650, Italy). NMRI mice were trained once per day for three consecutive days on an accelerating protocol (4-40 rpm over 5 min). Animals that after 3 days could not stay on the rotorod for 5 min were excluded. Twenty minutes after the last training, mice received an i.p. injection of VU0152100 (10 mg/kg), haloperidol (0.5 mg/kg), or vehicle (10 % tween 80). Forty minutes later (i.e., 1 h after the last training session), the mice were tested again on the rotorod and the latency to fall was measured up to 5 min. Immediately after the last test, the animals were quickly decapitated, and their brains were rapidly removed, frozen, and stored at −80°C until cfos in situ hybridization.
In vivo microdialysis The procedure was previously described (Weikop et al. 2004; Schmidt et al. 2011 ). Twenty to 30 min prior to surgery, NMRI or M 4 transgenic mice were treated with analgesic (Metacam, 5 mg/kg, s.c., Boehringer Ingelheim), then deeply anesthetized using sevoflurane (Baxter), and subsequently placed in a stereotaxic frame. Intracerebral guide cannulae (CMA Microdialysis AB, Sweden) were stereotaxically implanted into the brain to allow positioning of the dialysis probe in the striatum (AP +1.4 mm, ML +1.2 mm relative to bregma and DV −3.0 mm relative to skull surface; Franklin and Paxinos 2007) and fixed in place with one anchor screw and dental cement. After surgery, the animals were housed in individual cages and left to recover for at least 24 h. Correct placement of the probes was verified histologically at the end of the experiment.
The 2-mm microdialysis probe (CMA/7) was perfused at a rate of 1.8 μl/min with an artificial cerebrospinal fluid solution (147 mM NaCl, 4 mM KCl, and 2.3 mM CaCl 2 , adjusted to pH 6.5). Using a swivel and a bowl (Instech Laboratories, PA, USA), the animals were able to move freely during dialysis. The first five 20-min fractions were discarded to obtain stable basal values. After this, three 20-min fractions were collected to establish dopamine baseline levels. Subsequently, mice were injected with VU0152100 (0.1, 1.0, and 10 mg/kg) or vehicle and two 20-min fractions were collected. Mice were then injected with s.c. cocaine (30 mg/kg) or saline vehicle. All fractions were assayed immediately after collection using high-performance liquid chromatography (HPLC) with electrochemical detection (Weikop et al. 2004 ).
Total dopamine concentration in striatal tissue D1-M4-KO and wild-type (WT) mice were decapitated, the brains rapidly removed, and the striatum dissected, frozen, and stored at −80°C. On the day for the biochemical analysis, the tissue from each mouse was homogenized in 0.5 ml of 0.1 N perchloric acid containing 5 % EDTA. After centrifugation (14,000 rpm for 30 min), 200 μl of the supernatant was filtered through a glass filter (0.22 μm) and 20 μl was used for the dopamine analysis as described below.
Dopamine measurement Concentrations of dopamine in the microdialysis samples were determined by reversed-phase HPLC with electrochemical detection as previously described (Jeon et al. 2010) . Briefly, the HPLC system consisted of a HPLC pump (LC-20 AD, Shimadzu, Kyoto, Japan), a degasser (LC-27A, Waters, Denmark), a refrigerated microsampler (SIL-20 AC, Shimadzu), an amperometric detector (2465 EC, Waters), and a computerized data acquisition system (Empower, Waters). The electrochemical detector cell was equipped with a glassy carbon electrode operating at +0.7 V vs. Ag/ AgCl reference electrode. Typically, 15 μl samples were injected onto a Prodigy C18 column (100×2 mm I.D., 3-μm particle size, YMC Europe, Schermbeck, Germany). The mobile phase consisted of 93 % of 94.2 mM NaH 2 PO 4 , 0.98 mM octanesulfonic acid, 0.06 mM Na 2 EDTA, adjusted to pH 3.7 with 1 M phosphoric acid and 7 % acetonitrile (v/v). The flow rate was 0.25 ml/min. The limit of detection (at signal-tonoise-ratio 3) for dopamine was 7 fmol/15 μl.
In situ hybridization The procedure for in situ hybridization was previously described (Hjaeresen et al. 2008; Sørensen et al. 2012) . Briefly, coronal brain sections (15 μm) were cut through the frontal cortex (bregma 1.94→1.70 mm), striatum (bregma 1.10 → 0.86 mm), and hippocampus (−1.70 → −2.18 mm, only in experiment with M 4 transgenic mice) using a cryostat. Synthetic oligonucleotide DNA probes (DNATechnology) were used for visualization of cfos and M 4 receptor mRNA. The probe sequences were: cfos, 5′-CGG GCA GTG GCA CGT CTG GAT GCC GGC TGC CTT GCC TTC TCT GAC TGC-3′; M 4 , 5′-GTG GTG GAC AGC TCT GTG GGT GGT CGT TCC TTG GTG TTC TGG GTG GCA-3′.
Data analysis Data are presented as means ± standard errors of the means (SEM). Basal extracellular levels of dopamine in all groups were calculated as means of three fractions collected prior to drug or vehicle administration and were set to 100 %. All other values were expressed on a relative scale (mean ± SEM) as percentage of the basal (control) levels. The data were examined with two-way repeated measures ANOVA followed by Bonferroni-corrected pairwise comparisons. Additionally, area-under-the curve (AUC) values for the 60-120-min (AUC 60-120 min ) treatment interval were calculated for each animal and converted to percent of the AUC value of vehicle-treated mice (set as 100 %). Group differences in AUC data as well as cocaine self-administration, locomotor activity, and rotorod data were analyzed using one-way ANOVA followed by post hoc Dunnett's multiple comparison tests. In the microdialysis studies with transgenic mice, twoway repeated measures ANOVA followed by post hoc Bonferroni-corrected pairwise comparisons was used to compare treatment effects within the genotypes, as well as twoway ANOVA followed by post hoc Bonferroni-corrected pairwise comparisons to compare treatment effects between the genotypes. In the self-administration data, a higher variance was seen with cocaine treatment as compared to saline, probably due to the fact that some animals failed to learn the self-administration paradigm during the single session. To counter this variance in homogeneity, the number of nosepokes was square root-transformed before statistical analysis (Sørensen et al. 2008) . M 4 receptor and cfos mRNA expression was determined for each animal with a total of six measurements for each brain area. The mean of these measurements was used for further statistical analysis. Two-tailed, unpaired t tests were used to compare M 4 expression in D1-M4-KO and WT mice. One-way ANOVA followed by Bonferroni-corrected pairwise comparisons was used to compare cfos expression and total striatal tissue dopamine content. A p value<0.05 was considered statistically significant.
Results

VU152100
attenuates acute cocaine self-administration and cocaine-induced hyperlocomotion To investigate the effect of VU0152100 on the acute reinforcing effects of cocaine, we pretreated mice with VU0152100 (0.1-1.0 mg/kg) and then exposed them to the possibility to self-administer cocaine. One-way ANOVA showed a significant difference between test groups (F(3,44)04.05, p00.013). Post hoc Dunnett's multiple comparison test revealed that infusion of the cocaine peak dose (0.03 mg/kg/nose-poke) resulted in a significant increase in nose-poking during the 30-min session as compared to mice nose-poking for saline (p<0.05; Fig. 1a) . Pretreatment with VU0152100 (0.1 and 1.0 mg/kg) dosedependently reduced the self-administration of cocaine, reaching significance at the 1.0-mg/kg dose (p<0.01), where VU0152100 reduced self-administration to the level of saline (Fig. 1a) .
We also studied the effect of VU0152100 on cocaineinduced hyperlocomotion in mice. One-way ANOVA showed a significant difference between the test groups during the 3-h test period after treatment with cocaine 30 mg/kg (F(4, 27)0 4.38, p00.009). As expected, post hoc analysis showed that cocaine, as compared to saline, significantly increased locomotor activity measured as activity counts (p<0.01; Fig. 1b) . More importantly, pretreatment with VU0152100 (0.1-10 mg/kg) dose-dependently reduced the cocaine-induced hyperlocomotion by~50-60 %, reaching significance at the two highest doses (p<0.05; Fig. 1b) . VU0152100 does not affect motor coordination and balance To examine the possibility that the effects of VU0152100 on cocaine self-administration and cocaine-induced hyperlocomotion might be due to unwanted side effects on motor coordination or balance, we subjected VU0152100-treated mice to the rotorod test. One-way ANOVA showed a significant difference between the three test groups (F(2,26)0 25.03, p<0.001). Post hoc analysis showed that pretreatment with the prototypical antipsychotic and dopamine D 2 receptor antagonist haloperidol (0.5 mg/kg) significantly reduced the time spent on the rotorod (p<0.01), while a high dose of VU0152100 (10 mg/kg) was without effect (Fig. 1c) .
Previous studies have suggested that haloperidol-induced cfos activation, particularly in the caudate-putamen, reflects the manifestation of extrapyramidal motor side effects (Guo et al. 1992; Robertson et al. 1994) . Consequently, we compared the effect of pretreatment with VU0152100 to that of haloperidol on rotorod-induced cfos mRNA expression in the caudate-putamen (one-way ANOVA: F(2, 20)019.59, p<0.001) and nucleus accumbens (one-way ANOVA: F(2,20)010.97, p<0.001). Treatment with haloperidol (0.5 mg/kg) increased cfos mRNA expression in both areas (p<0.001 and p<0.01, respectively) compared to vehicle while VU0152100 (10 mg/kg) had no such effect (Fig. 2) . VU0152100 potently reduces cocaine-induced increases in striatal dopamine by activation of the M 4 receptor We used in vivo microdialysis to investigate whether the effects of VU0152100 in the behavioral studies might be mediated via effects on dopaminergic neurotransmission. The average baseline concentration of extracellular dopamine in the microdialysis samples from NMRI mice was 15±1.2 fmol/15 μl. Two-way repeated measures ANOVA showed a significant Fig. 1 Behavioral effects of the M 4 receptor PAM VU0152100 in NMRI mice. a In the acute self-administration model, cocaine (0.03 mg/kg/inf., black column; n014) induced a significant increase in the number of nose-pokes as compared to saline (white column; n0 11). Pretreatment with VU0152100 (0.1 and 1 mg/kg, i.p., gray columns; n013 and 11, respectively) dose-dependently inhibited nosepoking for cocaine, reaching significance at 1 mg/kg. b In the activity boxes, cocaine (30 mg/kg, s.c., black column; n06) induced hyperlocomotion as revealed by a significant increase in the number of total activity counts as compared to saline (white column; n06). Pretreatment with VU0152100 (0.1, 1, and 10 mg/kg, i.p., gray columns; n05-6) significantly reduced cocaine-induced hyperlocomotion. c Time spent on rotorod after i.p. pretreatment with vehicle (veh, white column), haloperidol (hal, 0.5 mg/kg; black column), or VU0152100 (VU, 10 mg/kg; gray column) (n09 in each group). Haloperidol significantly reduced time spent on the rotorod when compared to vehicle. In contrast, VU0152100 had no effect on rotorod performance. All data represent group mean ± SEM. #p<0.05, ##p<0.01 vs. vehicle i.p. followed by saline (veh-sal); *p<0.05, **p<0.01 vs. vehicle i.p. followed by cocaine (veh-coc); ‹‹p<0.01 vs. veh (one-way ANOVA followed by Dunnett's multiple comparison test) In situ hybridization analysis of cfos mRNA expression in NMRI mice after motor activation in the rotorod test. Treatment with haloperidol (hal, 0.5 mg/kg, i.p.; black columns) induced a significant increase in cfos expression in both the striatal regions, caudate-putamen (CPU), and nucleus accumbens (NAcc) compared to vehicle control (veh, white columns). Treatment with VU0152100 (VU, 10 mg/kg, i.p.; gray columns) alone gave no significant increase in cfos expression compared to vehicle. All data represent group mean ± SEM (n 06 per group). ‹‹p < 0.01, ‹‹‹p < 0.001 vs. veh (one-way ANOVA followed by Bonferroni-corrected pairwise comparisons) effect of time (F(11,319) 026.62, p < 0.001), treatment (F(5, 319) 016.33, p < 0.001), as well as a significant interaction (F(55,319) 05.82, p < 0.001). As expected, Bonferroni-corrected post hoc t tests revealed that cocaine injection (30 mg/kg) induced a significant increase (498± 74 %) in extracellular dopamine levels (p <0.01-0.05; Fig. 3 ). Pretreatment with all three doses of VU0152100 caused a pronounced reduction in the cocaine-induced dopamine increase in the striatum close to vehicle levels during the 60-120-min time interval (see Fig. 3 for the effect of the 1.0-mg/kg dose of VU0152100, 193±25 %). Analyzing the AUC values using one-way ANOVA confirmed these findings (F(4,24)010.97, p<0.001; see insert of Fig. 3 for the effect of all VU0152100 doses, p< 0.01 all doses, Bonferroni-corrected post hoc t tests).
To confirm that the effects of VU0152100 were, indeed, mediated by M 4 receptors, we next tested the effect of VU0152100 (1 mg/kg) on cocaine-induced striatal dopamine increases in M4-KO mice. Two-way ANOVA comparing AUCs from 60 to 120 min, covering the cocaine peak, showed a significant effect of genotype (F(1,31)05.73, p<0.05), treatment (F(2,31) 048.62, p < 0.001), and interaction (F(2,31)012.13, p<0.001). As in NMRI mice, Bonferronicorrected post hoc t tests revealed that injection of cocaine (30 mg/kg) compared to saline induced a significant dopamine increase in both WT (289±16 %) littermate control and M4-KO mice (259±20 %, both p<0.001; insert of Fig. 4) . As above, this increase could be prominently attenuated by pretreatment with VU0152100 (1 mg/kg) in WT mice (135± 13 %, p<0.001; insert of Fig. 4) . In contrast, in M4-KO mice, the cocaine-induced dopamine increase could not be attenuated by pretreatment with VU0152100 (1 mg/kg; 269±40 %; Fig. 4 and insert of Fig. 4) , indicating that M 4 receptors are necessary for the demonstrated effect of VU0152100. VU0152100 reduces cocaine-induced increases in striatal dopamine partly by activation of M 4 receptors co-localized with dopamine D 1 receptors Studies in a transgenic mouse strain in which the M 4 receptor has been selectively abrogated in D 1 receptor-expressing cells (D1-M4-KO) indicated that this subpopulation of M 4 receptors plays an import role in modulation of dopaminergic neurotransmission (Jeon et al. 2010; Dencker et al. 2011) . To further investigate the role of this subpopulation of M 4 receptors in mediating the effects of VU0152100, we tested the ligand on cocaine-induced striatal dopamine levels in D1-M4-KO mice. Two-way ANOVA comparing AUCs from 60 to 120 min, covering the cocaine peak, showed a significant effect of genotype (F(1, 22) 024.19, p<0.001), treatment (F(2, 22)040.86, p<0.001), and interaction (F(2, 22)06.20, p<0.01). Bonferroni-corrected post hoc t tests showed that cocaine injection (30 mg/kg) in WT mice induced a significant dopamine increase (298±15 %, p<0.01; insert of Fig. 5 ), and this effect could be reversed completely to the levels of saline by pretreatment with VU0152100 (1 mg/kg; 118±3 %, p<0.01; insert of Fig. 5 ). In D1-M4-KO mice, cocaine injection induced significantly higher dopamine levels than in WT mice (344±27 %, p<0.01; insert of Fig. 5 ). Interestingly, in these mice, pretreatment with VU0152100 (1 mg/kg) only partially blocked the cocaine-induced dopamine increase (199±10 %, p<0.001; Fig. 5 and insert of Fig. 3 Extracellular striatal dopamine levels in response to cocaine and VU0152100 (VU) in NMRI mice. Cocaine (30 mg/kg, veh-coc, black circles; n05) significantly increased extracellular dopamine compared to saline-treated controls (veh-sal, white circles; n05). This response was significantly reduced by pretreatment with VU0152100 (1 mg/kg, i.p.; gray circles; n05). #p<0.05, ##p<0.01 vs. veh-sal; *p< 0.05, **p<0.01 vs. veh-coc (two-way repeated measures ANOVA followed by Bonferroni-corrected pairwise comparisons). The insert shows cocaine-induced dopamine levels as AUC from 60 to 120 min. All three doses of VU0152100 caused a significant reduction in dopamine levels (n04-6). ##p<0.01 vs. veh-sal; **p<0.01 vs. veh-coc (one-way ANOVA followed by Dunnett's multiple comparison tests). All data represent group mean ± SEM inhibitory effects of VU0152100 on cocaine-induced striatal extracellular dopamine. The effects of VU0152100 in the mutant mouse strains were independent of potential baseline differences in dopamine or DOPAC tissue levels since these were similar in striatal tissues from M4-KO, D1-M4-KO, and corresponding WT control mice (Table 1) .
To determine to what extent M 4 receptors are co-expressed with dopamine D 1 receptors in our D1-M4-KO mice, we determined M 4 receptor mRNA levels in the caudate-putamen, nucleus accumbens, frontal cortex, and hippocampal subregions using in situ hybridization. M 4 expression was found to be strongly reduced in the caudate-putamen (−90 %; p<0.01, Fig. 4 Extracellular striatal dopamine levels in response to cocaine and VU0152100 in M4-KO mice. Cocaine (30 mg/kg, s.c., black circles; n05) significantly increased dopamine compared to saline in M4-KO mice (white circles; n06). The cocaine-induced dopamine increase could not be attenuated by pretreatment with VU0152100
(1 mg/kg, i.p., gray circles; n04) in M4-KO mice. #p<0.05, ##p< 0.01 vs. veh-sal in M4-KO mice (two-way repeated measures ANOVA followed by Bonferroni-corrected pairwise comparisons). The insert shows dopamine levels as AUC from 60 to 120 min in WT and M4-KO mice after saline (veh-sal), cocaine (veh-coc), or cocaine+VU0152100 (VU-coc) treatment. ###p<0.001 vs. veh-sal within genotype; ***p< 0.001 vs. veh-coc within genotype, $$$p<0.001 vs. the same treatment group between genotypes (two-way ANOVA followed by Bonferronicorrected pairwise comparisons; n04-8). All data represent group mean ± SEM Extracellular striatal dopamine levels in response to cocaine and VU0152100 in D1-M4-KO mice. Cocaine (30 mg/kg, s.c., black circles; n05) significantly increased extracellular dopamine compared to saline (white circles; n04). Pretreatment with VU0152100 (1 mg/kg, i.p., gray circles; n05) appeared to only partially reduce the effect of cocaine in D1-M4-KO mice. ##p<0.01 vs. veh-sal in D1-M4-KO mice (two-way repeated measures ANOVA followed by Bonferronicorrected pairwise comparisons). The insert shows dopamine levels as AUC from 60 to 120 min in WT and D1-M4-KO mice after saline (veh-sal), cocaine (veh-coc), or cocaine+VU0152100 (VU-coc) treatment. ##p<0.01, ###p<0.001 vs. veh-sal within genotype; **p<0.01, ***p<0.001 vs. veh-coc within genotype; $$p<0.001 vs. same treatment group between genotypes (two-way ANOVA followed by Bonferroni-corrected pairwise comparisons; n04-5). All data represent group mean ± SEM unpaired t test) and nucleus accumbens (−79 %; p<0.001) of D1-M4-KO compared to WT mice (Fig. 6a-c) while M 4 receptor mRNA levels did not differ in the other examined areas. This suggests that, in the measured striatal areas, M 4 receptors are predominantly expressed by D 1 -containing cells while in other measured brain regions M 4 receptors are predominantly found on non-D 1 -containing cells.
Discussion
The present study demonstrates, for the first time, that selective activation of the M 4 receptor, by PAM VU0152100, exerts a prominent inhibitory effect on cocaine-induced behavioral and biochemical effects in mice. The results of the present study are in agreement with previous studies where both the M 2 /M 4 partial agonist (5R,6R)6-(3-propylthio-1,2,5-thiadiazol-4-yl)-1-azabicyclo[3.2.1]octane (PTAC) and the M 1 /M 4 partial agonist xanomeline have exhibited functional dopamine antagonism and PTAC has been shown to decrease cocaine self-administration (Andersen et al. 2003; FinkJensen et al. 1998; Rasmussen et al. 2000; Shannon et al. 2000) . We found that VU0152100 (1.0 mg/kg) reversed cocaine effects in the acute cocaine self-administration model and in cocaine-induced hyperlocomotion (1 and 10 mg/kg). These findings are in agreement with our previous findings in a chronic self-administration model in M4-KO mice, showing that deficiency in M 4 receptors results in increased cocaine self-administration ). The present data, however, only investigate the effects of M 4 receptor activation on the acute reinforcing properties of cocaine, and investigation of the effects of VU0152100 in traditional chronic selfadministration model is needed to evaluate the chronic reinforcing effects of cocaine as well as relapse. An increase in extracellular dopamine levels in the striatum is central to the reinforcing effects of cocaine and other drugs of abuse (Wise 1996; Koob et al. 1998) . Using microdialysis, we found that the cocaine-induced striatal dopamine increase was almost abolished by pretreatment with VU0152100 at all three doses tested (0.1-10 mg/kg). This indicates that the inhibitory effects of VU0152100 on cocaine-mediated behaviors could be due to the reversal of cocaine effects on striatal dopamine levels. VU0152100 potentiates ACh-induced activation of M 4 receptors without potentiating activity at M 1 receptors or a number of other relevant G protein-coupled receptors (GPCRs), including dopamine D 1 and D 2 receptors as well as the dopamine transporter (Brady et al. 2008 , Suppl. Table 1 ). Besides weak antagonist activity at the 5HT 2B receptor, no other significant activity was detected in a Millipore GPCR Profiler TM screen (Brady et al. 2008) . Consequently, VU0152100 represents a valuable novel tool to study the mice while there were no significant differences in the frontal cortex (FC), hippocampal dentate gyrus (DG), and subfields CA3/CA1. Data represent group mean ± SEM. **p<0.01, ***p<0.001 vs. WT (Student's t test; n06) physiological effects of M 4 receptor activation. As further evidence that effects of VU0152100 on dopamine are, indeed, due to enhanced M 4 receptor activity, we found that the attenuating effect of VU0152100 on cocaine-induced increase in striatal dopamine was abolished in M4-KO mice. In the striatum, M 4 receptors are expressed on cholinergic interneurons as well as GABAergic medium spiny projection neurons, where they are highly co-expressed with D 1 receptors (Weiner et al. 1990; Bernard et al. 1992; Ince et al. 1997) . M 4 receptor has not been found on dopaminergic cell bodies. Muscarinic M 4 receptors located on striatal cholinergic interneurons or on cholinergic terminals can regulate acetylcholine release, which again modulates dopamine homeostasis via β2-subunit-containing nicotinic receptors on dopaminergic axons (Threlfell and Cragg 2011) . Since β2-nicotinic receptors facilitate or inhibit dopamine release depending on the dopaminergic tonus (Zhang and Sulzer 2004) , activation of M 4 receptor on cholinergic neurons may regulate dopamine release in a bidirectional manner (Threlfell et al. 2010 ). In addition, presynaptic M 4 receptor activation on GABAergic medium spiny neurons will lead to a decrease in GABA released from these neurons. Through a direct monosynaptic connection to midbrain dopaminergic neurons, this would most likely result in an increased release of dopamine. However, decreased GABAergic tone will also suppress GABA interneurons in the substantia nigra and the VTA, areas that do not express M 4 receptors. Reduced inhibition of these GABA interneurons will increase the inhibitory input to dopaminergic neurons in the midbrain and thereby reduce dopamine release (Tzavara et al. 2004) .
It has been proposed that M 4 receptors localized on medium spiny neurons antagonize D 1 receptor signaling (Jeon et al. 2010; Dencker et al. 2011) . As in M4-KO mice, we found that the cocaine-induced striatal dopamine increase was significantly reduced by pretreatment with VU0152100 in D1-M4-KO mice, indicating that D 1 receptor-expressing neurons are importantly involved in mediating the observed effects of VU0152100. However, since the cocaine-induced striatal dopamine increase was only partially abolished by VU0152100 in D1-M4-KO mice, M 4 receptor populations other than those on D 1 receptor-expressing neurons must also play a role.
M4-KO mice have previously been reported to exhibit increased dopamine release in the nucleus accumbens after administration of dopamine agonists (Tzavara et al. 2004; Brady et al. 2008) . In contrast, in the present study, we found no difference in the striatal dopamine response to cocaine between M4-KO and WT mice. The location of our microdialysis probe indicates that we must have sampled from both the dorsal (caudate-putamen) and ventral striatum (nucleus accumbens), with the majority of the dialysate deriving from the dorsal striatum. Threlfell et al. (2010) recently showed that ventral and dorsal striatal dopamine levels are differentially controlled by activation of muscarinic receptors on cholinergic interneurons. In the dorsal striatum, both M 2 and M 4 receptors are necessary for muscarinic regulation of dopamine release, while only M 4 receptors are necessary in the ventral striatum (Threlfell et al. 2010) . Together with our present data, this suggests that M 2 receptors localized on cholinergic interneurons could be sufficient to compensate for the loss of M 4 receptors in the regulation of dorsal striatal dopamine levels.
However, in D1-M4-KO mice, where M 4 receptors are preserved on striatal cholinergic interneurons, but are absent on GABAergic medium spiny projection neurons, cocaine induced a significantly greater dorsal striatal dopamine response, compared to WT mice. This suggests opposing roles for M 4 receptors on cholinergic interneurons and GABAergic projection neurons in the control of dopamine release. Since the reduction in M 4 receptor gene expression was relatively smaller in D1-M4-KO mice in the nucleus accumbens (79 %) compared to caudate-putamen (90 %; see Fig. 6 ), this indicates that a relatively higher proportion of cells express M 4 on non-D 1 cells in the nucleus accumbens than in the caudateputamen. This further suggests that M 4 receptors on cholinergic interneurons may play a greater role in the regulation of dopamine levels in the ventral than in the dorsal striatum, consistent with the findings by Threlfell et al. (2010) . Clearly, more detailed studies are needed to address the differential roles of muscarinic receptor subpopulations in the regulation of dopamine release.
Our recent finding of an attenuated cataleptic response to antipsychotic drugs in M4-KO mice could raise the concern that activation of the M 4 receptor might give rise to motor side effects ). However, VU0152100 had no effect on performance in the rotorod test at the highest dose used in the present study (10 mg/kg). This is in accordance with earlier studies in rats where doses of up to 100 mg/kg were used (Brady et al. 2008 ). Further consistent with this interpretation, we found no effect of VU0152100 on cfos induction after rotorod-induced motor activation. In contrast, haloperidol caused catalepsy that was accompanied by a pronounced increase in striatal cfos activation, which has been suggested to reflect the induction of motor side effects (Guo et al. 1992; Robertson et al. 1994) . Thus, the effects of VU0152100 in behavioral models reported here do not seem to be influenced by the effects on baseline levels of motor performance. Neither does VU0152100 seem to affect baseline dopamine levels during pretreatment time (0-40 min). However, this has not been investigated further.
It remains to be established why VU0152100 potently reduced cocaine-induced behaviors and striatal dopamine increases without affecting motor performance. Our finding suggests that the cocaine-mediated acetylcholine release (Imperato et al. 1992 ) is required for VU0152100 to increase the activity of the M 4 receptor and hereby decrease dopamine levels. In line with this result, VU0152100 potently blocked cocaine-induced behavior, whereas we did not observe any effect of VU0152100 in the rotorod test, where the acetylcholine tone induced by motor activation or stress (Imperato et al. 1989 ) most likely is moderate.
The results obtained in the present study support the findings in transgenic mice suggesting an important role for the M 4 receptor in the regulation of striatal dopaminergic neurotransmission. The development of selective PAM for the M 4 receptor will be very useful in further experiments elucidating the role of M 4 receptors in the regulation of dopaminergic neurotransmission and for the investigations of the therapeutic potential of this receptor. To further evaluate the potential of the M 4 receptor as a potential target for drug abuse, chronic experiments are warranted. This study indicates that PAMs of the M 4 receptor deserve attention as potential agents for future treatment of drug addiction as well as several other severe CNS disorders, where enhanced dopaminergic neurotransmission is a hallmark, e.g., schizophrenia.
